Posted by NINGBO INNO PHARMCHEM CO.,LTD.

In the realm of advanced drug development, pharmaceutical intermediates play a crucial role, serving as the building blocks for complex active pharmaceutical ingredients (APIs). Pirfenidone, a compound with the CAS number 53179-13-8, stands out as a significant pharmaceutical intermediate, particularly for its potent anti-fibrotic properties. Its application is primarily focused on the development of treatments for fibrotic diseases, most notably Idiopathic Pulmonary Fibrosis (IPF).

Pirfenidone is chemically described as 5-methyl-1-phenyl-2-(1H)-pyridone. Its significance lies in its ability to interfere with multiple fibrotic pathways. The Pirfenidone mechanism of action involves modulating the production of various growth factors and cytokines that promote fibrosis, such as transforming growth factor-beta (TGF-β) and tumor necrosis factor-alpha (TNF-α). By dampening these signaling cascades, Pirfenidone effectively inhibits the overproduction of extracellular matrix components, which are the hallmark of fibrotic tissue.

As a pharmaceutical raw material, Pirfenidone is typically supplied as a high-purity powder, often described as light yellow to white. This form makes it amenable to various formulation processes. The demand for Pirfenidone is intrinsically linked to the progress in IPF treatment drug development. With increasing recognition of its therapeutic potential, researchers and pharmaceutical companies are actively seeking reliable sources to buy Pirfenidone powder to integrate into their drug discovery and manufacturing pipelines.

The efficacy of Pirfenidone in clinical settings has been a driving force behind its increasing prominence. Its approval in several key markets for IPF treatment signifies its validated therapeutic value. This makes it a highly sought-after pharmaceutical intermediate for companies aiming to develop or expand their portfolio of anti-fibrotic therapies. The focus on fibrosis scar formation prevention further broadens the potential applications for Pirfenidone beyond IPF, potentially extending to other fibrotic conditions affecting organs like the liver, kidneys, and skin.

For manufacturers and researchers, understanding the specifications of Pirfenidone, such as its assay of 99% and low impurity profiles, is crucial. These metrics ensure the quality and reliability of the final drug product. The role of Pirfenidone as a key intermediate in creating advanced anti-fibrotic therapies underscores its importance in the pharmaceutical landscape. As research progresses, Pirfenidone is expected to remain a central compound in the fight against fibrotic diseases.